Merck KGaA

Merck KGaA: Strong 2nd Quarter, Guidance raised

Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued

Merck KGaA: Dr. Matthias Heinzel, buy

Merck KGaA: Peter Guenter, buy

Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide